U.S. FDA Approves VYALEV For Adults Living With Advanced Parkinson's Disease
U.S. FDA Approves VYALEV For Adults Living With Advanced Parkinson's Disease
美國FDA批准VYALEV用於愛文思控股帕金森病患者。
- VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
- Adults treated with VYALEV reported superior improvement in "on" time without troublesome dyskinesia, compared to oral immediate-release carbidopa/levodopa1
- VYALEV allows for personalized dosing based on individual needs, morning, day and night
- VYALEV是首個也是唯一一個用於治療晚期帕金森病運動波動的皮下24小時持續輸注的左多巴基治療方案
- 接受VYALEV治療的成年人報告在不酷動的"on"時間上獲得了更好的改善,相較於口服即時釋放的卡比多巴/左多巴1
- VYALEV允許根據個人需求進行個性化劑量,早晨、白天和晚上
NORTH CHICAGO, Ill., Oct. 17, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved VYALEV (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD).
伊利諾伊州諾斯芝加哥,2024年10月17日/美通社/ -- 艾伯維(紐交所:ABBV)今天宣佈,美國食品藥品監督管理局(FDA)已批准VYALEV(芙卡比多巴和芙左多巴)作爲第一個也是唯一一個用於治療成人晚期帕金森病(PD)運動波動的皮下24小時左多巴基治療方案。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。